University of Lille

There is a lack of high-quality data to inform risk-stratified long-term thrombosis prevention strategies in patients with persistently positive antiphospholipid antibodies (aPL). We aimed to determine independent clinical and biologic predictors of thrombosis among persistently aPL-positive patients. Patients positive for aPL according to the Revised Sapporo Classification Criteria are eligible for inclusion in the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry. Registrants with at least 1 year of follow-up were included in this study. We fit Cox proportional hazards models to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for independent predictors of thrombosis. In unadjusted analyses, based on 1067 patients with a mean follow-up of 4.43 years (4,727 person-years), history of thrombosis, hematologic disease (autoimmune haemolytic anaemia and/or thrombocytopenia), microvascular disease, obesity, renal disease, sedentary lifestyle, baseline anticoagulant use, and family history of early cardiovascular disease occurred more frequently (P < .05) among patients with new thrombosis (n = 93) than among those without new thrombosis (n = 974). After adjustment, independent predictors of new thrombosis were history of thrombosis (HR 2.34, 95% CI 1.14 to 4.81, P = .02) and hematologic disease (HR 1.95, 95% CI 1.19 to 3.18, P = .01); there was a trend for history of microvascular disease (P = .06) and obesity (P = .08). In this prospective analysis, history of thrombosis and hematologic disease each conferred an approximately twofold increased risk of new thrombosis in persistently aPL-positive patients. These findings can guide future clinical trial designs and inform patient management decisions.

Cet article propose une analyse réflexive et critique sur une recherche appliquée visant la conception d’outils de communication pro-climat, centrée sur la production d’une vidéo dédiée aux « bibliothèques d’objets ». L’étude articule quatre volets complémentaires : (1) une analyse des conditions de production et des discours d’intention (finalités, publics visés, cadrages) ; (2) une lecture sémiotique à orientation structurale de la vidéo en tant que texte ; (3) une évaluation de la réception par des publics réels, via questionnaires et discussions de groupe ; (4) une relecture critique de l’ensemble du projet, pour éclairer les potentialités et les limites d’une communication pro-climat qui poursuit une forme de syncrétisme axiologique.

In health promotion, traditional evidence-based approaches have shown limitations in capturing the complexity of real-world interventions and in integrating the experiential knowledge of field actors. The CEKHP (Capitalize, collect, and circulate Experiential Knowledge in Health Promotion) method was developed in France as a response to this gap, offering a structured process for documenting and disseminating experiential knowledge. This method paper aims to describe the CEKHP methodology and demonstrate its added value for research and practice in health promotion, using a hospital-based pediatric oral health education program as a case study. The CEKHP method involves a five-step process (framing, data collection, analysis, validation, dissemination) facilitated by a trained third party in collaboration with project leaders. Data were collected through semi-structured interviews, then analyzed thematically based on a guiding capitalization question. The process produced a structured "capitalization sheet" co-validated by stakeholders. The method captured valuable contextual, procedural, and strategic elements of the program, highlighting barriers (e.g., perception of educational actions as secondary) and facilitators (e.g., institutional support, multidisciplinary collaboration). It enabled a reflexive analysis of the implementation and provided actionable insights for adaptation and transferability to other hospital settings. The CEKHP method bridges a critical gap in health promotion by formalizing the collection of tacit knowledge from practitioners. It contributes to a broader understanding of intervention applicability, supports reflective practice, and enhances the knowledge base beyond conventional evidence. As such, it is a promising tool to complement evidence-based strategies with practice-informed insights.

This book contains the full text papers abstracts of which were presented at THERMEC 2025, the 13th International Conference on Processing and Manufacturing of Advanced Materials, held between June 30 and July 04, 2025, in Tours, France, under the co-sponsorship of the University of Tours and the University of Lille and also under the auspices of professional organizations from Japan, Korea, France, Italy, The Netherlands, Germany, Brazil, Austria, India, and Canada. The Conference brought together researchers and engineers-technologists whose professional activities relate to various aspects of processing, fabrication, structure-property evaluation, and the applications of both ferrous and nonferrous materials, including biomaterials, innovative materials, and advanced characterisation techniques.

This study evaluates energy conversion and heat transfer in a germicidal chamber employing gold nanorods (AuNRs) irradiated with an infrared laser (808 nm, 0.8 W) to generate heat via localized surface plasmon resonance. The investigation focused on the preliminary selection of chamber materials and the geometry of the bottom surface supporting the AuNRs as the heat source in a photothermoablation application. A one-way multiphysics and multiscale approach was applied, integrating nanoscale heating phenomena with a macroscale fluid and heat flow. The validated 2D numerical model shows satisfactory agreement with experimental data and is suitable for further design analyses. Computational Fluid Dynamics (CFD) simulations were conducted to determine temperature and entropy distributions, mean and maximum temperatures, and Nusselt numbers, allowing the assessment of the energy conversion process under different configurations and AuNR dimensions. The results indicate that a configuration with a gradually descending stepped structure enhances interactions between nanoparticles and the fluid, increasing the internal energy and producing elevated temperatures. Under optimal conditions, a temperature rise of approximately 75 °C was achieved. These findings demonstrate that integrating material selection, surface geometry, and nanoparticle absorbance optimization can significantly improve the efficiency of bacterial inactivation in germicidal chambers. This study provides a framework for future investigations on fully three-dimensional multiscale and multiphysical modeling, as well as a targeted AuNR design to maximize the thermal performance.

Purpose This paper aims to examine the significance of focusing on object movement in visual ethnography to enhance our understanding of object circulation. Design/methodology/approach This paper is grounded in the theoretical framework of the mobility turn proposed by the sociologist Urry (2007) and anchored in post-human ontology. Findings Concentrating on object circulation provides novel insights in consumer research, with the need for visual ethnography centered more on the movement of objects in consumers’ personal spaces. A qualitative research protocol is discussed. Originality/value The contribution is both methodological and theoretical. It stresses the relevance of adopting an approach focused on object movement in visual ethnography and provides conceptual insights into the mobility turn based on a different framework than previously used in sociocultural research. Tracking the movement of objects in public and private, multisited and multitemporal settings can elucidate specific aspects of object circulation and complement more human-centric methods.

Levosimendan may facilitate weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) and improve survival, but supporting evidence remains limited. To assess whether early administration of levosimendan reduces the time to successful VA-ECMO weaning in patients with severe but potentially reversible cardiogenic shock. Randomized, double-blind, placebo-controlled trial conducted across 11 intensive care units (ICUs) in France. Between August 27, 2021, and September 10, 2024, 205 adult patients with acute cardiogenic shock who had started VA-ECMO in the preceding 48 hours were enrolled. Final follow-up was completed on November 10, 2024. Patients were randomized in a 1:1 ratio to receive levosimendan, 0.15 μg/kg per minute, to be increased to 0.20 μg/kg per minute after 2 hours (n = 101), or placebo (n = 104). The primary outcome was time to successful ECMO weaning within 30 days following randomization. Secondary outcomes included ECMO-, mechanical ventilation-, and organ failure-free days, ICU and hospital lengths of stay, serious adverse events, and all-cause 30- and 60-day mortality. Among the 205 randomized patients (median age, 58 [IQR, 50-67] years; 149 [72.7%] male), main cardiogenic shock etiologies were postcardiotomy (79 [38.5%]), acute myocardial infarction (56 [27.3%]), and myocarditis (28 [13.7%]). Treatment dose was increased to 0.20 ± 0.01 μg/kg per minute in 93% of patients receiving levosimendan and in 96% of those receiving placebo. Within 30 days, 69 of 101 patients (68.3%) had a successful ECMO weaning in the levosimendan group compared with 71 of 104 (68.3%) in the placebo group (risk difference, 0.0% [95% CI, -12.8% to 12.7%]; subdistribution hazard ratio, 1.02 [95% CI, 0.74-1.39]; P = .92). In the levosimendan and placebo groups, respectively, median ECMO duration (5 [IQR, 4-7] days vs 6 [IQR, 4-11] days; P = .53), mean ICU length of stay (18 [SD, 15] days vs 19 [SD, 15] days; P = .42), and 60-day mortality (27.7% vs 25.0%; risk difference, 2.7% [95% CI, -9.0% to 15.3%]; P = .78) did not differ significantly. Ventricular arrhythmias occurred more frequently with levosimendan (18 [17.8%] vs 9 [8.7%]; absolute risk difference, 9.2% [95% CI, 0.4%-18.1%]). Among patients with severe but potentially reversible cardiogenic shock supported by VA-ECMO, early levosimendan administration did not significantly reduce the time to successful weaning of ECMO compared with placebo. ClinicalTrials.gov Identifier: NCT04728932.